Publications

Biotechnology Letters

 Watari A, Hashegawa M, Muangman T, Yagi K, Kondoh M
 Biotechnology Letters - vol. 37 1177-1185 (2015)

Claudins constitute a family of at least 27 proteins with four transmembrane domains, and play a pivotal role in maintaining tight-junctions seals in diverse epithelial tissues. The expression of claudin-4 often changes in intestinal tissues of inflammatory bowel disease and various human cancers. Therefore, claudin-4 is a promising target for treatment of these diseases. In […]

Oncogene

 Bharadwaj U. ET, Mancini ADJT
 Oncogene - vol. 34 1341-1353 (2015)

Signal transducer and activator of transcription (STAT) 3 regulates many cardinal features of cancer including cancer cell growth, apoptosis resistance, DNA damage response, metastasis, immune escape, tumor angiogenesis, the Warburg effect, and oncogene addiction and has been validated as a drug target for cancer therapy. Several strategies have been employed to identify agents that target […]

Molecular endocrinology

 Yang YHC, Vilin YY, Roberge M, Kurata HT, Johnson JD
 Molecular endocrinology - vol. 28 406-417 (2014)

Pancreatic β-cell death plays a role in both type 1 and type 2 diabetes, but clinical treatments that specifically target β-cell survival have not yet been developed. We have recently developed live-cell imaging-based, high-throughput screening methods capable of identifying factors that modulate pancreatic β-cell death, with the hope of finding drugs that can intervene in […]

Disease models & mechanisms

 Voisset C, Daskalogianni C, Contesse M, Mazars A, Arbach H, Le Cann M, Soubigou F, Apcher S, Fåhraeus R, Blondel M
 Disease models & mechanisms - vol. 7 435-444 (2014)

Epstein-Barr virus (EBV) is tightly associated with certain human cancers, but there is as yet no specific treatment against EBV-related diseases. The EBV-encoded EBNA1 protein is essential to maintain viral episomes and for viral persistence. As such, EBNA1 is expressed in all EBV-infected cells, and is highly antigenic. All infected individuals, including individuals with cancer, […]

European Journal of Medicinal Chemistry

 Röhrig UF, Majjigapu SR, Chambon M, Bron S, Pilotte L, Colau D, Van Den Eynde BJ, Turcatti G, Vogel P, Zoete V, Michielin O
 European Journal of Medicinal Chemistry - vol. 84 284-301 (2014)

Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator of immune responses and therefore an important therapeutic target for the treatment of diseases that involve pathological immune escape, such as cancer. Here, we describe a robust and sensitive high-throughput screen (HTS) for IDO1 inhibitors using the Prestwick Chemical Library of 1200 FDA-approved drugs and the Maybridge […]

Biochemical Pharmacology

 Normand A, Rivi??re E, Renodon-Corni??re A
 Biochemical Pharmacology - vol. 91 293-300 (2014)

Homologous Recombination (HR) plays an essential role in cellular proliferation and in maintaining genomic stability by repairing DNA double-stranded breaks that appear during replication. Rad51, a key protein of HR in eukaryotes, can have an elevated expression level in tumor cells, which correlates with their resistance to anticancer therapies. Therefore, targeted inhibition of Rad51 through […]

Clinical Cancer Research

 Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC
 Clinical Cancer Research - vol. 20 3198-3210 (2014)

PURPOSE: Enzalutamide, a second-generation antiandrogen, was recently approved for the treatment of castration-resistant prostate cancer (CRPC) in patients who no longer respond to docetaxel. Despite these advances that provide temporary respite, resistance to enzalutamide occurs frequently. Androgen receptor (AR) splice variants such as AR-V7 have recently been shown to drive castration-resistant growth and resistance to […]

All our screening libraries

Partners